Appendix 2 Chemotherapy drugs and concurrent complementary therapy
1. Frischer H., Ahmad T. Severe generalized glutathione reductase deficiency after antitumour chemotherapy with BCNU″[1,3-bis(chloroethyl)-1-nitrosourea]. J Lab Clin Med. 1977;89(5):1080-1091.
2. Osiecki H. Cancer: a nutritional/biochemical approach, 2nd edn. Brisbane: BioConcepts Publishing; 2003.
3. Braun L., Cohen M. Herbs and natural supplements, an evidence-based guide, 3rd edn. Sydney: Elsevier; 2005.
4. Salerno E. Pharmacology for health professionals. St Louis: Mosby; 1999.
5. Kurbacher C.M., et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996;103(2):183-189.
6. Tsutani H., et al. Pharmacological studies of retinol palmitate and its clinical effect in patients with acute non-lymphocytic leukemia. Leuk Res. 1991;15(6):463-471.
7. Branda R.F., et al. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood. 1998;92(7):2471-2476.
8. Teicher B.A., et al. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother Pharmacol. 1994;34(3):235-241.
9. Conklin A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37(1):1-18.
10. Wietrzyk J., et al. Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res. 2001;21(6A):3893-3896.
11 Davis L., Kuttan G. Effect of Withania somnifera on cyclophosphamide-induced urotoxicity. Cancer Lett. 2000;148(1):9-17.
12. Badary O.A. Taurine attenuates Fanconi syndrome induced by ifosimide without compromising its anti-tumour activity. Oncol Res. 1998;10(7):355-360.
13. Mills S., Bone K. The essential guide to herbal safety. St Louis: Churchill Livingstone; 2005.
14. Heisler T., et al. Peptide YY and vitamin E inhibit hormone-sensitive and -insensitive breast cancer cells. J Surg Res. 2000;91(1):9-14.
15. Prasad K.N., et al. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994;22(3):233-245.
16. Prasad K.N., et al. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr. 1999;18(1):13-25.
17. Nakagawa Y., et al. Relationship between ascorbic acid and alpha-tocopherol during diquat-induced redox cycling in isolated rat hepatocytes. Biochem Pharmacol. 1991;25:42(4):883-888.
18. Fullerton S.A., et al. Induction of apoptosis in human prostatic cancer cells with beta-glucan (maitake mushroom rythrocytese). Mol Urol. 2000;4(1):7-13.
19. Georgian L., et al. The protective effect of vitamin A and vitamin C on the chromosome-damaging activity of CCNU. Morphol Embryol (Bucur). 1986;32(4):241-245.
20. Gadjeva V., et al. Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU. Toxicol Lett. 2003;144(3):289-294.
21. Blasiak J., et al. Genotoxicity of streptozotocin in normal and cancer cells and its modulation by free radical scavengers. Cell Biol Toxicol. 2004;20(2):83-96.
22. Mahesh T., Menon V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother Res. 2004;18(2):123-127.
23. Yilmaz O., et al. Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the gluthione, malonaldehyde, and fatty acid levels in rythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem. 2002;86(3):530-539.
24. Jonas C.R., et al. Plasma antioxidant status after high dose chemotherapy: a randomised trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000;72(1):181-189.
25. Hoffman R., et al. Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562. Br J Cancer. 1989;59(3):347-348.
26. Durken M., et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant. 1995;15(5):757-762.
27. Beer T.M., et al. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol. 2004;27(5):535-541.
28. Wigington D.P., et al. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res. 2004;24(5A):2905-2912.
29. Trump D.L., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89–90(1–5):519-526.
30. Johnson C.S., et al. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev. 2002;21(2):147-158.
31. Saunders D.E., et al. Additive inhibition of RL95-2 endometrial carcinoma cell growth by carboplatin and 1,25 dihydroxyvitamin D3. Gynecol Oncol. 1993;51(2):155-159.
32. Meara D.J., et al. Role of calcium in modulation of toxicities due to cisplatin and its analogs: a histochemical approach. Anticancer Drugs. 1997;8(10):988-999.
33. Lovat P.E., et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer. 2000;88(6):977-985.
34. Lissoni P., et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5(2):126-129.
35. Jung B., Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006;66(20):9789-9793.
36. Ghielmini M., et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer. 1999;80(7):1058-1061.
37. Antunes L.M., et al. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose dependent study. Pharmacol Res. 2000;41(4):405-411.
38. Ali B.H., Al Moundhri M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: some recent research. Food Chem Toxicol. 2006;44(8):1173-1183.
39. Pace A., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927-931.
40. Weisman R.A., et al. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. Otolaryngol Head Neck Surg. 1998;118(5):597-602.
41. Kalemkerian G.P., et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer. 1998;83(6):1102-1108.
42. Melli G., et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008;214(2):276-284.
43. Bougnoux P. n-3 polyunsaturated fatty acids and cancer. Curr Opin Clin Nutr Metab Care. 1999;2(2):121-126.
44. Jakubowicz-Gil J., et al. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol. 2005;69(9):1343-1350.
45. Francescato H.D., et al. Protective effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis. Kidney Blood Press Res. 2004;27(3):148-158.
46. Sliwinski T., et al. Zinc salts differentially modulate DNA damage in normal and cancer cells. Cell Biol Int. 2009;33(4):542-547.
47. Lissoni P., et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemo-endocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer in patients in a poor clinical state. J Pineal Res. 1999;23(1):15-19.
48. Savarese D.M., et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501-513.
49. Anderson P.M., et al. Oral glutamine reduces the duration and severity of stomatitis after cancer chemotherapy. Cancer. 1998;83:1433-1439.
50. Buckley J.E., et al. Hypomagnesemia after cisplatin combination therapy. Arch Intern Med. 1982;144:2347.
51. Van de Loosdrecht A.A., et al. Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia. Acta Oncol. 2000;39:239-240.
52. Sadzuka Y., et al. Modulation of cancer chemotherapy by green tea. Clin Cancer Res. 1998;4(1):153-156.
53. Sonnenbichler J., et al. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999;290(3):1375-1383.
54. Slavik M., et al. Changes in serum copper and zinc during treatment with anticancer drugs interfering with pyridoxal phosphate. Adv Exp Med Biol. 1989;258:235-242.
55. Radu L., et al. The combined action of thiotepa and lomustine cytostatics, of estradiol hormone and of vitamins E and A on Walker tumor chromatin structure. Rom J Endocrinol. 1993;31(3–4):149-153.
56. Lialiaris T., et al. Enhancement and attenuation of cytogenetic damage by vitamin C in cultured human lymphocytes exposed to thiotepa or L-ethionine. Cytogenet Cell Genet. 1987;44(4):209-214.
57. Studzinski G.P., et al. Potentiation by 1-alpha, 25 dihdroxyvitamin D3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. J Natl Cancer Inst. 1986;76(4):641-648.
58. Kim C.H. Increased expression of N-acetylglucosaminyltransferase-V in human hepatoma cells by retinoic acid and 1alpha,25-dihydroxyvitamin D3. Int J Biochem Cell Biol. 2004;36(11):2307-2319.
59. Makishima M., et al. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br J Cancer. 1998;77(1):33-39.
60. Vukelja S.J., et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1989;111(8):688-689.
